Data as of Mar 07
| +0.13 / +1.00%|
Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL.
|Timothy P. Walbert||Chairman, President & Chief Executive Officer|
|Amy Grahn||Senior VP-Clinical Development & Operations|
|Robert J. de Vaere||CFO, Secretary, EVP & Head-Investor Relations|
|Jeffrey W. Sherman||Chief Medical Officer & EVP-Regulatory Affairs|
|Jeffrey D. Kent||Senior VP-Medical Affairs & Outcomes Research|